Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
Abstract Introduction Atopic dermatitis (AD) can require long-term therapy. Few real-world studies have evaluated long-term effectiveness from the patients’ perspective. The aim of this study was to evaluate patient-reported outcomes (PROs) during long-term dupilumab treatment. Methods Adults with m...
Main Authors: | Alexa B. Kimball, Dimittri Delevry, Min Yang, Chien-Chia Chuang, Zhixiao Wang, Gaëlle Bégo-Le-Bagousse, Bruno Martins, Eric Wu, Brad Shumel, Jessie Wang, Debra Sierka, Jingdong Chao, Bruce Strober |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-08-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-023-00965-5 |
Similar Items
-
Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’
by: Mike Bastian, et al.
Published: (2024-02-01) -
Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023-06-01) -
Conjunctivitis in patients with atopic dermatitis treated with dupilumab
by: Sandra Ferreira, et al.
Published: (2020-05-01) -
Alopecia areata after dupilumab for atopic dermatitis
by: Krystal Mitchell, MBA, et al.
Published: (2018-03-01) -
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01)